Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904175 · ClinicalTrials.gov registry record
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
A clinical trial of Leukemia and Non-Hodgkin's Lymphoma, sponsored by Duke University.
- Completed
- Registry status
- 48
- Enrollment target
- 1
- Study location
NCT01904175 is a study of Leukemia and Non-Hodgkin's Lymphoma that has completed, run by Duke University. The registered enrollment target is 48 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01904175, a study of Leukemia and Non-Hodgkin's Lymphoma, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Allogeneic transplantation is used to treat many malignant and non-malignant diseases. The investigators and others have shown that less toxic preparative regimens (reduced intensity or 'mini' transplants) allow reliable allogeneic engraftment and durable remissions, significantly broadening the population of patients who may be offered this therapy to those who are older and more infirmed. The field is now focusing on the period post transplant for approaches to immune recovery leading to improved outcomes. The primary objective of this registry is to catalogue data from patients who undergo standard of care reduced intensity allogeneic transplantation.
Conditions Studied
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01904175
The ClinicalTrials.gov registry entry for NCT01904175 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (90% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT01904175 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01904175 about?
NCT01904175 is a clinical study titled "Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant". Allogeneic transplantation is used to treat many malignant and non-malignant diseases. The investigators and others have shown that less toxic preparative regimens (reduced intensity or 'mini' transplants) allow reliable allogeneic engraftment and durable remissions, significantly broadening the pop...
What is the current status of trial NCT01904175?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2013-08. Estimated completion is 2016-04.
What conditions does trial NCT01904175 study?
This clinical trial studies the following conditions: Leukemia, Non-Hodgkin's Lymphoma, Myeloma, Hodgkin's Disease, Myelodysplasia.
Who is sponsoring clinical trial NCT01904175?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01904175 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.